processes for the preparation of benzyl-benzene derivatives substituted with glycopyranosyl

专利摘要:
PROCESS FOR THE PREPARATION OF BENZYL-BENZENE DERIVATIVES SUBSTITUTED WITH GLYCOPYRANOSIL AND USE OF THE SAME. The present invention relates to the processes for the preparation of a benzyl benzene derivative substituted with glycopyranosyl of the general formula III, wherein RI is defined according to claim 1.
公开号:BR112012007085B1
申请号:R112012007085-1
申请日:2010-09-24
公开日:2020-10-13
发明作者:Dirk Weber；Tobias FIEDLER；Christian Filser；Rainer Hamm；Simone Orlich；Matthias POST；Svenja Renner；Xiao-Jun Wang；Thomas Wirth
申请人:Boehringer Ingelheim International Gmbh；
IPC主号:

专利说明:

The present invention relates to a process for the preparation of benzyl benzene derivatives substituted with glycopyranosyl of the formula H1,
wherein the substituents R1 and R2 and R1 are defined as follows. In addition, the present invention relates to the processes for preparing the process intermediates and starting materials for the preparation of benzyl-benzene derivatives substituted with glycopyranosyl. In addition, the present invention relates to the uses of the processes according to the invention. Background of the invention
WO 2005/092877 describes benzene derivatives substituted with glycopyranosyl of the general formula
wherein the groups R1 to R6 and R7a, R7b, R7c are as defined therein. Such compounds have a valuable inhibitory effect on the SGLT sodium-dependent glucose cotransporter, particularly SGLT2.
WO 2006/117359 describes a crystalline form of 1-chloro-4- (β-D-glycopyran-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) -benzyl] -benzene and its synthesis.
WO 2006/120208 describes various methods of synthesizing the compounds of the formula
wherein R1 means cyclobutyl, cyclopentyl, cyclohexyl, R-tetrahydrofuran-3-yl, S-tetrahydrofuran-3-yl or tetrahydropyran-4-yl. Example XVIII in it refers to the synthesis of 1-chloro-4- (β-D-glycopyran-1-yl) -2- (4- (S) -tetrahydrofuran-3-yloxy-benzene) -benzene. According to variant E in it, (S) -3- [4- (5-iodo-2-chloro-benzyl) -phenoxy] -tetrahydrofuran is reacted with 7-PrMgCI / LiCI, in THF, at low temperatures, to form an organometallic intermediate. In an aqueous finalization step, an aqueous NH4 Cl solution (25% by weight) is added. After the addition of methyl tert-butyl ether, the organic layer comprising the intermediate product is separated. In efforts to expand the scale of this process, it was observed that the separation of the aqueous and organic phases can cause difficulties, for example, by the formation of three phases. Purpose of the invention
The aim of the invention is to find advantageous processes for the preparation of benzyl-benzene derivatives substituted with glycopyranosyl of formula III; in particular, powerful processes with which the product can be obtained in high yields, high enantiomeric or diastereoisomeric purity and which allow the product to be manufactured on a commercial scale, with a low technical expense and a high performance in space / time.
Another objective of the present invention is to find a commercially viable process for the preparation of benzyl benzene derivatives substituted with glycopyranosyl of formula III, comprising an aqueous finalization step that allows a safe and easy separation of the aqueous and organic phase.
Another objective of the present invention is to provide processes for preparing the starting materials of the aforementioned manufacturing method.
Other objectives of the present invention will become apparent to the skilled person directly from the preceding and following description. Purpose of the invention
In a first aspect, the present invention relates to a process for preparing a benzyl-benzene derivative substituted with glycopyranosyl of the general formula III,
wherein R1 means C1-3-alkyl, cyclobutyl, cyclopentyl, cyclohexyl, (R) -tetrahydro-furan-3-yl, (S) -tetrahydrofuran-3-yl or tetrahydropyran-4-yl; and R2, independently of each other, means hydrogen, (C1-s-alkyl) carbonyl, (C1-alkyl) oxycarbonyl, phenylcarbonyl, phenyl- (C1-3-alkyl) -carbonyl, phenyl-C1-3-alkyl , ally, RaRbRcSi, CRaRbORc, where two adjacent R2 groups can be linked together to form a SiRaRb, CRaRb or CRaORb-CRaORb bonding group; and R 'means hydrogen or C1-6 alkyl; Ra, Rb, Rc, independently of each other, mean C1-4-alkyl, phenyl or phenyl-C1-3-alkyl, although the alkyl groups may be mono- or polysubstituted by halogen; L1, independently of each other, are selected from fluorine, chlorine, bromine, C1-3 alkyl, C1-4 alkoxy and nitro; although the phenyl groups mentioned in the definition of the groups mentioned above can be mono- or polysubstituted with L1; comprising steps (S2) to (S5): (S2): reacting the organometallic compound of formula VI
where R1 is defined as above and M means Li, Mg or MgQ, where Q means Cl, Br, I or an organic portion; with a gluconolactone of the general formula IV
wherein R2 is as defined above, in an organic solvent or a mixture of two or more organic solvents; and (S3): adding an aqueous solution comprising one or more acids, such that the reaction mixture forms an aqueous phase and an organic phase, whereby the organic phase has a pH in the range of about 0 to 7; and (S4): separating the organic phase comprising the adduct obtained in step (S2) from the aqueous phase; and (S5): react the adduct obtained with water or an alcohol R'-OH, where R 'means C1-6 alkyl, or a mixture of them, in the presence of one or more acids.
It was found that the separation of the aqueous and organic phases in step (S3) is safer and, therefore, more suitable for a commercial scale process, when the organic phase has a pH in the range of about 0 to 7. Thus, in step (S3), the aqueous solution comprising one or more acids is to be added to the reaction mixture in such a way that the organic phase has a pH in the range of about 0 to 7. As a consequence of the improvement in phase separation, the entire process for preparing a benzyl-benzene derivative substituted with glycopanosis of general formula III proved to be a powerful process with which the product is obtained in high yields and in a high purity at commercially viable scales. An additional advantage is that solvent changes during the process are kept to a minimum and that the duration of time for the entire process is minimized.
In the variant E above described in example XVIII of WO 2006/120208, an aqueous finalization step was also carried out with the aqueous solution of NH4CI (25% by weight). However, in efforts to expand the scale of this process, it was observed that the separation of the aqueous and organic phases can cause difficulties, for example, through the formation of three phases. According to this example, a pH of about 9 to 10 is measured in the organic phase, which is outside the preferred pH range according to the eta-pa (S3) of the present invention.
In another aspect, the present invention relates to a use of the process for preparing a benzyl benzene derivative substituted with glycopyranosyl of the general formula III,
wherein R1 means C1-3-alkyl, cyclobutyl, cyclopentyl, cyclohexyl, R-tetrahydrofuran-3-yl, S-tetrahydrofuran-3-yl or tetrahydropyran-4-yl; and R2, independently of each other, mean hydrogen, (C1.8-alkyl) carbonyl, (C4 s-alkyljoxycarbonyl, phenylcarbonyl, phenyl- (C1_3-alkyl) -carbonyl, phenyl-Cvs-alkyl, ally, RaRbRcSi, CRaRbORc , where two adjacent groups R2 may be linked together to form a SiRaRb, CRaRb or CRaORb-CRaORb bonding group; and R 'means hydrogen or C1-6-alkyl; Ra, Rb, Rc, independently of each other, mean Ci-4-alkyl, phenyl or phenyl-Ci-3-alkyl, although the alkyl groups can be mono- or polysubstituted by halogen; L1, independently of each other, are selected from fluorine, chlorine, bromine, Ci- 3-alkyl, C1-4 alkoxy and nitro; although the phenyl groups mentioned in the definition of the aforementioned groups can be mono- or polysubstituted with L1; as described above and below for the synthesis of a benzyl-benzene derivative substituted with glycopyranosyl of general formula II,
wherein R1 is defined as further comprising step (S6): (S6) reacting the substituted benzyl-benzene derivative with glycopyranosyl of general formula III with a reducing agent. Detailed description of the invention
Unless otherwise indicated, groups, residues and substitutes, particularly R1, R2, R ', Ra, Rb, Rc, L1, M, X, are defined as above and below.
If residues, substituents or groups occur several times in a compound, they can have the same or different meanings.
In the processes and compounds according to this invention, the following meanings of groups and substituents are preferred: R1 preferably means R-tetrahydrofuran-3-yl or S-tetrahydro-furan-3-yl. Ra, Rb, Rc, independently of each other, preferably mean methyl, ethyl, n-propyl or i-propyl, tert-butyl or phenyl; more preferably methyl. R2 preferably means hydrogen, methylcarbonyl, ethylcarbonyl or trimethylsilyl. More preferably, R2 means trimethylsilyl. R 'preferably means hydrogen, methyl or ethyl, more preferably methyl.
The starting material of formula VI can be obtained by methods known to one skilled in the art. The process according to the invention preferably comprises the additional step (S1) to obtain the organometallic compound of formula VI: (S1): reacting a compound of formula V
where R1 is defined as above and X means Br, I or triflate; with magnesium, lithium, a magnesium Grignard reagent or an organic lithium compound, in an organic solvent or a mixture of two or more organic solvents, producing an organometallic compound of formula VI
where R1 is defined as above and M means Li, Mg or MgQ, where Q means Cl, Br, I or an organic portion.
In the following, the processes according to this invention are described in detail.
The benzyl-benzene derivative substituted with glycopyranosyl of formula III can be synthesized from D-gluconolactone or a derivative thereof, by reacting the desired benzylbenzene compound in the form of an organometallic compound of formula VI (Scheme 1).
Scheme 1: Addition of an Organometallic Compound to Gluconolactone

In step (S1), the organometallic compound of formula VI is prepared by reacting the compound of formula V with magnesium, lithium, a magnesium Grignard reagent or an organic lithium compound, in an organic solvent or a mixture of two or more organic solvents. The reaction is a so-called halogen-metal exchange reaction or an insertion of the metal into the carbon-halogen bond. The group X preferably means iodine. The reaction can be carried out with elemental magnesium or lithium. In the event that no spontaneous reaction occurs, promoters such as iodine, tetrachloromethane or iodomethane can be added. Alternatively, the reaction can be carried out with an organic lithium compound, such as Ci-e-alkyl lithium, preferably n-, see- or tert-butyl lithium. Preferably, the reaction is carried out with a magnesium Grignard reagent, such as C3-alkyl-aryl-magnesium chlorides or bromides, for example, isopropyl or sec-butyl magnesium chloride or bromide, or tert-butyl magnesium bromide, phenyl magnesium chloride or bromide. The compounds derived from magnesium or lithium thus obtained can optionally be transmetallated with metal salts, such as, for example, cerium trichloride, zinc chloride or bromide, indium chloride or bromide, or bromide or copper chloride, to form alternative organometal (VI) compounds, suitable for addition. As promoters, additional salts such as lithium bromide and / or lithium chloride can be added at the beginning of, during, or at the end of step (S1). Alternatively, such promoters can be added at the beginning or during step (S2). More preferably, the compound of formula V is reacted with a mixture of isopropylmagnesium chloride and lithium chloride. The molar ratio of the Grignard reagent, in particular the C3_4-alkyl magnesium chloride or bromide, for example, iPrMgCI, to lithium bromide and / or lithium chloride, in particular LiCI, is preferably in the range from 1: 10 to 10: 1, more preferably about 1: 1. The 1: 1 mixture of iPrMgCI: LiCI is commercially available, for example, in a concentration of about 12 to 16%, w / w, in tetrahydrofuran, also called "Turbogrignard solution". Preferred amounts of magnesium, lithium, a magnesium Grignard reagent or an organic lithium compound over the compound of formula V are in the range of about 0.5 to 2 moles, more preferably about equimolar. It has been found that quantities less than about 1 mol result in losses in yield and quantities greater than about 1 mol result in the formation of unwanted by-products. The reaction is carried out in an organic solvent or a mixture of two or more organic solvents. Preferred solvents are selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl methyl ether (TBME), diethyl ether, heptane, toluene, benzene, dioxane, methylcyclohexane, hexane, dimethyl sulfoxide, dichloromethane and chloroform. The most preferred solvents are tetrahydrofuran and 2-methyltretrahydrofuran. The reaction can be carried out in a temperature range of -100 to + 50 ° C, preferably from -70 to 10 ° C, more preferably from -40 to -10 ° C. The reaction can be monitored by HPLC technology, NIR, IV, for example. A preferred reaction time is between 10 min and 600 min. The reaction product of formula VI can be isolated, although such isolation is not necessary. The preceding reactions are preferably carried out under an inert gas atmosphere. Argon and nitrogen are preferred inert gases.
In step (S2), the gluconolactone of formula IV is added to the compound of formula VI in an organic solvent or a mixture of two or more organic solvents. Preferred solvents are those described in relation to step (S1) above. Preferably, gluconolactone is added to the reaction mixture obtained in step (S1). The R2 substituents preferably mean trimethylsilyl, triethylsilyl, triisopropyl, tributylsilyl, tert-butyl-dimethylsilyl, tert-butyldiphenylsilyl, acetyl, benzyl, benzoyl, ally, methoxymethyl, tetrahydropyranyl. More preferably, R2 means trimethylsilyl. Preferred amounts of gluconolactone over the organometallic compound of formula VI are in the range of about 0.8 to 3 moles, more preferably about 1 to 2 moles, most preferably about 1.06 moles. The reaction can be carried out in a temperature range of 100 to + 50 ° C, preferably from -70 to 10 ° C, more preferably from -20 to -5 ° C. The reaction can be monitored by HPLC, NMR, GC, NIR or IV technology, for example. A preferred reaction time is between 15 min and 600 min. The reaction product of formula VI can be isolated. The preceding reactions are preferably carried out under an inert gas atmosphere. Argon and nitrogen are the preferred inert gases.
In step (S3), an aqueous solution comprising one or more acids is added to the reaction mixture obtained in step (S2), such that the reaction mixture forms an aqueous phase and an organic phrase, whereby the organic phase has a pH in the range of about 0 to 7. In principle, all inorganic or organic acids can be used to achieve the desired pH range. Preferred acids are organic acids, such as citric acid, tartaric acid, oxalic acid, succinic acid, acetic acid, chlorine acetic acid, dichloric acetic acid or trifluoroacetic acid, or inorganic acids , such as hydrochloric acid, sulfuric acid or nitric acid. The acid can be an ammonium salt, such as ammonium chloride. The acid can be part of a buffer system, such as acetic acid / acetate (for example, acetic acid and sodium acetate), dihydrogenphosphate / hydrogen phosphate (for example, KH2PO4 / Na2HPO4), TRIS (Tris (hydroxymethyl) - aminomethane) or HEPES (2- (4- (2-hydroxyethyl) -1- piperazinyl) -ethanesulfonic acid). The most preferred acids are citric acid and acetic acid, in particular citric acid. The aqueous solution may additionally comprise mixtures of the acids mentioned above or additionally salts, for example, sodium chloride, potassium chloride, sodium bromide, potassium bromide, lithium chloride, lithium bromide or mixtures thereof. . The amount of one or more acids in the aqueous solution is preferably such that the reaction mixture forms an aqueous phase and an organic phase, so that the organic phase has a pH in the range of about 0 to 7. A range most preferred pH range is about 1 to 6, even more preferably about 1 to 4, more preferably about 2 to 3. It has been found that a pH in a preferred pH range as described above allows good separation of the aqueous and organic phase. Without being bound by any theory, it is assumed that at pH values in the preferred ranges, the intermediate product has its highest stability. At pH values below the preferred, three phases were observed. Again without being bound by any theory, it is believed that at low pH values, the protecting groups on the glycopyranosyl ring can be cleaved so that the unprotected intermediate product can form an additional phase. At pH values above the preferred ones, it has been found that phase separation is difficult or impossible, due to the formation of emulsions.
The pH value can be measured in the organic phase using methods well known to the chemist, such as pH electrodes and pH indicators, including indicator papers and test rods. Preferably, the pH value is measured at the given temperature of the organic phase, more preferably at a temperature between about 0 ° C and 40 ° C, even more preferably between about 10 ° C and 30 ° C, for example , at room temperature (about 20 to 25 ° C). The pH value can be measured in the organic phase after phase separation, for example, immediately after separation or several hours later.
A preferred concentration of one or more acids, such as, for example, citric acid, in the aqueous solution is in the range of about 2 to 30% by weight, more preferably about 5 to 20% by weight, more preferably about 10% by weight. The volume of the aqueous solution in relation to the volume of the reaction mixture obtained in step (S2) is preferably in the range of about 0.1 to 5, more preferably of about 0.2 to 2, even more preferably of about from 0.2 to 1, more preferably about 0.3 to 0.6, for example, about 0.4. The aqueous solution can be added to the reaction mixture preferably at a temperature in the range of about -50 to 40 ° C, even more preferably of about -10 to 25 ° C. The addition of the aqueous solution can preferably be carried out within at least 15 min, even more preferably 60 min.
In order to obtain an even better separation of the aqueous and organic phases, it may be advantageous to add one or more additional organic solvents to the reaction mixture in this reaction step or during the previous reaction steps (S1) or (S2). Preferred additional organic solvents can be selected from the group consisting of 2-methyltetrahydrofuran, toluene, isopropyl acetate, ethyl acetate, n-butyl acetate, tert.-butyl methyl ether, n-heptane, acetone, methyl ethyl ketone, methyl - lysobutyl ketone, dioxane, tetrahydrofuran, methylcyclohexane and hexane. The most preferred additional organic solvent is 2-methyltetrahydrofuran. The amount of the additional organic solvent in relation to the total amount of the organic phase of the reaction mixture is preferably in the range of about 2% by weight to 60% by weight, more preferably from about 5% by weight to 50% by weight. weight, even more preferably from about 10% by weight to 40% by weight, more preferably from about 15 to 35% by weight.
Before adding the additional organic solvent, the volume of the organic phase can be reduced by distilling the reaction mixture, preferably under reduced pressure. Distillation is preferably carried out at a temperature below or equal to about 35 ° C. The reaction mixture obtained after the completion of step (S3) exhibits an aqueous phase and an organic phase, whereby the reaction product according to step (S2) is found mainly in the organic phase.
In step (S4), the organic phase comprising the adduct obtained in step (S2) is separated from the aqueous phase. The methods for separating the liquid phases are well known to someone skilled in the art. The phase separation is preferably carried out at a temperature in the range of about -20 to 50 ° C, more preferably of about 0 to 30 ° C. The obtained organic phase comprises most of the adduct obtained in step (S2). The aqueous phase can be washed one or more times with an organic solvent or a mixture of organic solvents and the organic phases can be combined. Preferred organic solvents are described above in relation to steps (S1), (S2) and (S3). Before carrying out the next reaction step, a partial volume or the total volume of one or more organic solvents is preferably distilled, preferably under reduced pressure. Distillation is preferably carried out at a temperature below or equal to approximately 35 ° C.
In step (S5), the adduct obtained in step (S4) is reacted with water or an alcohol R'-OH, where R 'means Ci-6-alkyl, or a mixture of them, in the presence of one or more acids. R'-OH alcohol is preferably selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, n-butanol, tert-butanol or mixtures thereof. The preferred alcohol is methanol. The alcohol is preferably used in an amount exceeding an equimolar amount, in such a way that it serves as a solvent as well. In principle, all inorganic or organic acids can be used in the reaction step. With the addition of the one or more acids, preferably a pH below about 7 is to be obtained. A preferred pH range is about 0 to 7, more preferably about 0 to 4, even more preferably about 1 a 2. The acid is preferably selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, citric acid, tartaric acid, oxalic acid and succinic acid. A more preferred acid is hydrochloric acid, which can be used, for example, as a solution of HCI in ethanol, HCI in propanol, HCI in dioxane. Alternatively, HCI gas can be used. A preferred reaction temperature is in the range of about -50 to 50 ° C, more preferably about 0 to 30 ° C, most preferably about 15 to 25 ° C. A total conversion to the product of formula III is advantageously achieved by subsequent distillation, preferably under reduced pressure and preferably at a temperature below or equal to about 35 ° C. Complete conversion has been found to improve when, during distillation, an additional amount of R'-OH alcohol is added to the reaction mixture. The reaction is preferably completed within 120 min. The reaction can be monitored using HPLC, for example. Upon completion of the reaction, the remaining acid in the reaction mixture is preferably partially or completely neutralized by the addition of one or more bases. A preferred pH after adding the base is preferably in the range of about 5 to 6. Preferred bases are, for example, triethylamine, ammonia, trimethylamine, n-alkylamines (such as, for example, methyl lamina, ethylamine), diisopropylethylamine (DIPEA), sodium carbonate, sodium bicarbonate, potassium carbonate, ethanolamine, 1,4-diazabicyclo [2.2.2] octane (DABCO), 1.8 -diazabicycle [5.4.0] undec-7-ene (DBU). Triethylamine is the most preferred base. A partial or total amount of the solvent is preferably distilled, preferably under reduced pressure. A solvent, or a mixture of solvents, is advantageously added and at least partially distilled again. The addition of the solvent with subsequent distillation can be repeated one or more times to reduce the water content of the reaction mixture. The solvent is preferably selected from the group consisting of acetonitrile, propionitrile, tetrahydrofuran and dioxane. Finally, another solvent or mixture of solvents can be added. A preferred solvent is selected from the group consisting of methylene chloride, ethyl acetate, isopropyl acetate, chloroform, 1,2-dichloroethane, dimethoxyethane, N, N'-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide , tetrahydrofuran, 2-methyltetrahydro-furan, dioxane, diethyl ether and tert.-butyl methyl ether. A preferred solvent is dichloromethane. Advantageously, the water content of the resulting reaction mixture is determined, for example, by means of Karl-Fischer, GC, NMR, IV or NIR titration. The water content of the resulting reaction mixture is preferably below 5000 ppm, more preferably below 2000 ppm.
The glucose derivatives of formula II can be synthesized by means of step (S6), which is a reduction of the aomeric carbon-oxygen bond of compound III (Scheme 2). Scheme 2: Reduction of compound III
R ', R1 and R2 are defined as above. A preferred meaning of R2 is hydrogen or tri- (C1-3-alkyl) silyl, such as trimethylsilyl. R 'preferably means hydrogen or C1-4 alkyl, in particular methyl or ethyl.
In step (S6), the reduction can be carried out with one or more reducing agents, in the presence of one or more Lewis acids or without a Lewis acid. Suitable reducing agents include, for example, silanes (such as, for example, triethylsilane, 1,1,3,3-tetramethyldisiloxane (TMDS), tripropylsilane, triisopropylsilane (TIPS), diphenylsilane), those with - borane plexuses (such as, for example, sodium cyanoborohydride (NaCNBH3), zinc borohydride) or aluminum hydrides (such as, for example, aluminum lithium hydride (LiAIH4), diisobutylaluminum hydride nium or lithium triisopropylaluminum hydride (Li (iPr) sAIH)). A preferred reducing agent is triethylsilane. The amount of the reducing agent in relation to the compound of the formula III is preferably in the range of about 1 to 5 moles, more preferably about 2 to 4 moles, more preferably about 2.7 moles. Suitable Lewis acids are, for example, aluminum chloride, boron etherate trifluoride, trimethylsilyl triflate, titanium tetrachloride, tin tetrachloride, scandium triflate, zinc iodide, or triflate copper (II). Aluminum chloride is a preferred Lewis acid. The amount of Lewis acid relative to the compound of formula III is preferably in the range of about 1 to 5 moles, more preferably about 2 to 4 moles, most preferably about 2.1 moles. The reaction is carried out in an organic solvent or a mixture of organic solvents. Preferred solvents are, for example, acetonitrile, dichloromethane, propionitrile, tetrahydrofuran or dioxane. Preferred solvents are acetonitrile, methylene chloride and mixtures thereof. Preferred reaction temperatures are between about -50 ° C and 50 ° C, more preferably between about 0 and 30 ° C, most preferably between about 10 to 20 ° C. Preferably, the reaction mixture obtained in step (S4) is added to a mixture of one or more Lewis acids, one or more organic solvents and one or more reducing agents. The addition of the reaction components is preferably done in a range of about 15 to 600 min, more preferably in a range of between 45 and 120 min. The reaction mixture is preferably stirred, for example, for about 0 to 600 min, more preferably for about 30 to 120 min, at a temperature in the range of about -80 to 50 ° C, preferably about 0 to 35 ° C, more preferably about 15 to 25 ° C.
Alternatively, in step (S6), hydrogen can be used as a reducing agent. This reaction can be carried out in the presence of a transition metal catalyst, such as palladium on charcoal, Raney nickel, platinum oxide, palladium oxide. The reaction conditions and the suitable solvents in a hydrogenation are known to someone skilled in the art. For example, suitable solvents are tetrahydrofuran, ethyl acetate, methanol, ethanol, water, or acetic acid, and the appropriate reaction temperatures are in the range of about - 40 ° C to 100 ° C and hydrogen pressures are in the range of about 1 to 10 mm Hg (1 to 10 Torr).
The preceding reduction synthesis steps are preferably carried out under an inert gas atmosphere. Argon and nitrogen are preferred inert gases.
After the end of the reaction, water is added to the reaction mixture. During the addition, the internal temperature is preferably in the range of 20 to 40 ° C. A preferred range of time for the addition is preferably 15 to 120 min. Instead of water, an aqueous solution can be added. Suitable aqueous solutions are, for example, salt solutions, such as sodium chloride (brine) solution, potassium chloride solution, NaHCOj solution, NajCOs solution or K2CO3 solution. Alternatively, aqueous buffer solutions, such as ammonium chloride solutions, acetic acid / acetate, KH2PO4 / Na2HPO4, TRIS (Tris (hydroxymethyl) -aminomethane), HEPES (2- (4- (2-hydroxyethyl) acid, can be used -1-piperazinyl) -ethanesulfonic).
According to a preferred embodiment, the reaction is partially distilled, under reduced pressure or under atmospheric pressure, and at a temperature below or equal to about 35 ° C, more preferably below or equal to about 55 ° C .
Then, the reaction mixture is cooled to about 30 to 35 ° C and the aqueous phase and the organic phase are separated. The aqueous phase can be washed one or more times with an organic solvent or a mixture of organic solvents and the organic phases can be combined.
Advantageously, an organic solvent or a mixture of organic solvents is added to the organic phase and part of, or the total amount of, solvents is distilled, preferably under reduced pressure and at a temperature below or equal to about 35 °. C, more preferably below or equal to about 40 to 50. Suitable solvents are toluene, isopropyl acetate, n-butyl acetate, ethyl acetate, tert.-butyl methyl ether, n- heptane, acetone, methyl ethyl ketone, methyl isobutyl ketone, dioxane, tetrahydrofuran, benzene, methylcyclohexane, hexane, 2-methyltetrahydrofuran or mixtures thereof. Toluene is a preferred solvent.
The product can be obtained by crystallization, for example, as described in WO 2006/117359, or as described below.
Alternatively, in an additional step before crystallization, an organic solvent or a mixture of organic solvents is added to the organic phase, at a temperature below or equal to about 40 to 50 ° C. Suitable solvents are acetonitrile, propionitrile, toluene, isopropyl acetate, n-butyl acetate, ethyl acetate, tert-butyl methyl ether, n-heptane, acetone, methyl ethyl ketone, methylisobutyl ketone, dioxane, tetrahydrofuran, benzene, methylcyclohexane, hexane, 2-methyl-tetrahydrofuran or mixtures thereof. Acetonitrile is a preferred solvent.
Then, the percentage of acetonitrile in the organic phase is determined with GC technology (gas chromatography). The percentage of acetonitrile is in the range of about 10 to 40%, preferably between about 20 and 30%.
Then, the seeding crystals are added to the organic phase, in a temperature range of about 40 to 48 ° C, preferably around 45 ° C. Advantageously, stirring is continued in this temperature range for about 10 to 240 min, more preferably 15 to 120 min.
Then, the organic phase is cooled from a temperature range of about 40 to 48 ° C to a temperature range of about 15 to 20 ° C, in the time range of 30 to 120 min, preferably about 60 min.
Then, water or an aqueous solution is added to the organic phase. The addition of water or the aqueous solution is preferably done in a temperature range of about 15 to 25 ° C, preferably 20 ° C. In addition, the addition is preferably done in a range of about 30 to 120 min, preferably about 60 min. Suitable aqueous solutions are, for example, salt solutions, such as sodium chloride solution (brine), potassium chloride solution, NaHCO3 solution, Na2COs solution or K2CO3 solution. Aqueous buffer solutions are, for example, ammonium chloride, acetic acid / acetate, KH2PO4 / Na2HPO4, TRIS (Tris (hydroxymethyl) -aminomethane) solutions, HEPES (2- (4- (2-hydroxyethyl) acid - 1-piperazinyl) -ethanesulfonic).
Then, preferably, the mixture is cooled to a temperature range of about 0 to 5 ° C, in a time range of about 45 to 120 min, preferably about 60 min. Then, preferably, the mixing is continued by stirring for about 3 to 24 h, preferably about 12 h, in a temperature range of about 0 to 5 ° C.
The product is then collected using suitable filtration or centrifugation techniques and the collected product is then washed with an organic solvent. Suitable solvents are acetonitrile, propionitrile, toluene, isopropyl acetate, n-butyl acetate, ethyl acetate, tert.-butyl methyl ether, n-heptane, acetone, methyl ethyl ketone, methylisobutylcetone, dioxane, tetrahydrofuran, benzene, methylcyclohexane, hexane, 2-methyltetrahydrofuran or mixtures thereof. The preferred solvent is toluene.
Advantageously, the isolated product is then dried using suitable drying equipment, in a time range of about 1 to 192 h, preferably about 5 to 96 h, at temperatures of about 20 to 20 120 ° C, preferably about 20 to 70 ° C. Drying is preferably carried out under reduced pressure and under an inert gas atmosphere. Argon and nitrogen are the preferred inert gases.
The gluconolactone of formula IV can be synthesized starting from the D - (+) - glyconic-delta-lactone acid of formula IVa (Scheme 3). Scheme 3: Synthesis of gluconolactone IV

The methods for the transformation of the D - (+) - glyconic-delta-lactone acid of formula IVa, to produce the desired gluconolactone of formula IV, where R2 is defined as above, are well known to someone skilled in the art. In the following, a preferred method is described in detail where R2 means trimethylsilyl.
A suspension of D - (+) - glyconic acid-delta-lactone of formula IV, in an organic solvent or mixture of organic solvents, one or more bases and one or more catalysts, is treated with one or more silylating agents. Preferred organic solvents are tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, or also tert.-butylmethyl ether (TBME), diethyl ether, heptane, toluene, benzene or mixtures thereof. Preferred bases are 4-methylmorpholine, diisopropylethylamine (DIPEA), triethylamine (TEA), NaHCO3, K2CO3, Na2CO3, KOH, NaOH. Preferred catalysts are 4-dimethylaminopyridine, pyridine, triethylamine. Preferred silylating agents are chlorotrimethylsilane, hexamethyldisilazane, bis (trimethylsilyl) acetamide, trimethylsilylimidazole, trimethylsilyldimethyldiamine, N, N'-bistrimethylsilylurea or mixtures thereof. The base is preferably employed in a molar excess, more preferably in a range of about 4 to 10 moles, more preferably about 5 to 8 moles with respect to the starting compound of formula IV. A preferred amount of the catalyst is in the range of about 0.001 to 0.5 mol, more preferably about 0.01 to 0.2 mol with respect to the starting compound of formula IV. With respect to the silylating agent, a preferred amount is in the range of about 4 to 10 moles with respect to the starting compound of formula IV. The reaction is preferably carried out at a temperature in the range of about -50 to 100 ° C, more preferably about -10 to 30 ° C. The addition of the silylating agent is preferably done in a period of about 1 to 6 hours. After the addition is complete, the reaction mixture is stirred, preferably within about 1 to 6 hours, at a temperature of about -50 to 100 ° C, more preferably about -10 to 30 ° C, in particular from 0 to 20 ° C. Conversion can be monitored with known methods, such as HPLC analysis, GC, NMR, IV. Then, an organic solvent or a mixture of organic solvents is added and the mixture is preferably cooled to about 0 to 10 ° C. The preferred organic solvents are n-heptane, 2-methyltetrahydrofuran, dioxane, tert.-butylmethyl ether, diethyl ether, toluene, benzene, isopropyl acetate, n-butyl acetate, ethyl acetate. Then, water or an aqueous solution is added, preferably at a temperature in the range of 0-10 ° C. The aqueous solution can comprise a salt, such as sodium chloride solution, potassium chloride, NaHCOs, NasCOs, K2CO3, or a buffer system, such as ammonium chloride, acetic acid, acetate , dihydrogen phosphate, hydrogen phosphate, TRIS (Tris (hydroxymethyl) -aminomethane), HEPES (2- (4- (2-hydroxyethyl) -1-piperazinyl) -ethanesulfonic acid). After the addition is complete, the mixture can be continued to be stirred, preferably at an internal temperature in the range of about -50 to 100 ° C, more preferably about 0 to 35 ° C. After stirring is discontinued, the phases are separated and the organic layer is washed in succession one or more times with water or an aqueous solution, as described above. Then, the organic solvent is distilled, preferably at a temperature below or equal to about 40 ° C, in particular under reduced pressure. One or more organic solvents are added to the residue. Preferred organic solvents are n-heptane, methylcyclohexane, tert.-butylmethyl ether, 2-methyltetrahydrofuran, ethyl acetate, isopropyl acetate, n-butyl acetate, toluene, benzene. The resulting solution can be filtered. Then, the solvent is distilled off, preferably at a temperature below or equal to about 40 ° C, preferably under reduced pressure. The water content of the residue can be determined by Karl-Fischer, GC, NMR or IV analysis. The product is obtained as an oil.
The compound of formula V can be synthesized starting from the ketone of formula VII, by means of a reduction (Scheme 4). Scheme 4: Synthesis of the compound of formula V

The methods for reducing a ketone of formula VII to produce the desired compound of formula V, where X is Br, I or triflate and R1 is defined as above, are well known to someone skilled in the art. In the following, a preferred method is described in detail where X means iodine.
A reducing agent is added to a solution of the ketone of formula VII and a Lewis acid in an organic solvent or a mixture of organic solvents. Suitable reducing agents are, for example, silanes, such as 1,1,3,3-tetramethyldisiloxane, triethylsilane and triisopropylsilane, or boroidides, such as NaBH4, or aluminum hydrides, such as LiAIH4. The preferred Lewis acids are aluminum chloride, BF3 * OEt2, tris (pentafluorfenyl) borane, trifluoroacetic acid, hydrochloric acid, or lnCl3. Suitable organic solvents are, for example, halogenated hydrocarbons, such as dichloromethane and 1,2-dichloroethane, toluene, benzene, hexane, acetonitrile and mixtures thereof, more preferably toluene. The reaction temperature is preferably in the range of about -30 to 80 ° C, preferably about 10 to 30 ° C, even more preferably about 0 to 25 ° C. The amount of the reducing agent, as well as the amount of Lewis acid, is preferably in the range of about 1 to 2 moles, more preferably about 1.2 moles with respect to the ketone. The addition is preferably carried out within about 1 to 5 hours, more preferably between about 1 to 2 hours. After the addition is complete, the mixture is stirred for preferably an additional 1 to 2 hours. Conversion can be determined by HPLC, GC, NMR or IV analysis. Subsequently, any excess of the reducing agent is extinguished by methods known to someone skilled in the art. For example, the reaction mixture is treated with a ketone or an alcohol, such as acetone, methyl ethyl ketone, methanol, ethanol, 2-propanol or n-butanol, and stirred for about 1 to 5 hours, preferably at a temperature in the range of about 20 to 30 ° C. Any residual content of the reducing agent can be analyzed using GC, NMR or IV. It is advantageous to include an additional reaction step where the reaction mixture is finished with an aqueous solution. The aqueous solution (preferred pH range 1 to 14) can comprise an acid, such as hydrochloric acid, sulfuric acid, nitric acid, citric acid, tartaric acid, oxalic acid, succinic acid, acid acetic acid, trifluoroacetic acid, or a buffer system, such as ammonium chloride, acetic acid / acetate, dihydrogen phosphate, hydrogen phosphate, TRIS (Tris (hydroxymethyl) -aminomethane), HEPES (2- (4- (2-hydroxyethyl) -1-pipe-razinyl) -ethanesulfonic), or a base, such as NaHCOs, K2CO3, Na2CO3, KOH, NaOH. The reaction mixture is stirred, for example, for about 30 to 120 min, at an internal temperature of about 40 to 60 ° C. After completion, the phases are separated and a partial or total amount of the organic solvent is distilled from the organic phase, preferably at a temperature below or equal to about 80 ° C, preferably under reduced pressure. The product of formula V can be obtained by crystallization. For this, an organic solvent or a mixture of organic solvents is added to the residue, preferably at a temperature in the range of about 50 to 80 ° C. A mixture of toluene and ethanol is preferred, where a preferred weight ratio is about 1: 1 to 1: 20, more preferably about 1: 8. Toluene can be replaced with acetonitrile, tert.-butyl methyl ether, n -heptane, benzene, methylcyclohexane, 2-methyltetrahydrofuran, isopropyl acetate (IPAc), ethyl acetate (EtOAc) or n-butyl acetate. Ethanol can be replaced by 2-propanol, n-butanol, acetone, methyl ethyl ketone, water or tetrahydrofuran. The reaction mixture is cooled, preferably to a temperature in the range of about 0 to 50 ° C, more preferably to about 20-40 ° C. Preferably, seeding crystals are added, which can be obtained, for example, according to WO 2006/117359. Stirring can be continued at this temperature, for example, for 30 to 60 min. Then, the mixture can be further cooled, for example, to about -10 ° C to 5 ° C, and stirred for an additional time. The product of formula V can be collected, for example, on a filter or on a centrifuge, and washed with a suitable solvent or mixture of solvents, such as ethanol. The product can be dried, preferably at a temperature below or equal to about 60 ° C, more preferably about 40 ° C, and under reduced pressure.
The formula VII ketone can be synthesized starting from the formula VIII ketone (Scheme 5)
Scheme 5: Synthesis of the formula VII ketone
The methods for replacing, in particular by nucleophilic substitution, the group Z with the group O-R1, where R1 is defined as above and Z preferably means fluorine, are well known to someone skilled in the art. Group X is defined as above. In the following, a preferred method is described in detail.
The ketone of formula VIII is reacted with an R1-OH alkanol, where R1 is defined as above, in an organic solvent or mixture of two or more organic solvents. The amount of the R1-OH alkanol is preferably in the range of about 1 to 2 moles, more preferably 1.1 moles per mole of the ketone of formula VIII. This reaction is preferably carried out in the presence of a base, such as alkali C1-4 alkoxides, alkaline carbonates, alkali hydroxides, alkaline phosphates, tri (C1-3 alkyl) amines and other organic bases containing N. Examples of preferred bases are lithium or sodium or potassium tert-butanolate, sodium or potassium or cesium carbonate, sodium or potassium hydroxide, tripotassium phosphate, triethylamine, ethyldiisopropylamine, bis (trimethylsilyl) ) sodium amide (NaHMDS), diazabicycloundecene (DBU), 1,4-diazabicyclo [2.2.2] octane (DABCO) or mixtures thereof. The most preferred bases are selected from sodium or potassium tert-butanolate, sodium or potassium hydroxide, cesium carbonate, a mixture of cesium carbonate and potassium carbonate, or mixtures thereof. The amount of the base is preferably in the range of 1 to 5 moles, more preferably about 1 to 2 moles, in particular about 1.2 moles of base per mole of intermediate VIII. In case the base is a carbonate, phosphate or mixtures thereof, the total amount of the base is more preferably in the range of 2 to 4 moles of base, more preferably about 3 moles of base per mole of intermediate VIII. A more preferred base is potassium tert-butanolate, for example, as a solution approximately 10 to 30% by weight in tetrahydrofuran. Suitable organic solvents are, for example, tetrahydrofuran, 2-methyltetrahydrofuran or dioxane. A preferred time period for adding the reagents is about 1 to 20 hours, preferably 2.5 to 6.5 hours. A preferred temperature during the addition of the reagents is in the range of about -20 to 70 ° C, more preferably about 15 to 25 ° C. After the completion of the addition, the mixture is preferably stirred for a period of about 5 to 500 min, at a temperature in the range of about -20 to 70 ° C, more preferably about 15 to 25 ° C. The reaction can be monitored, for example, through HPLC, NMR or IV analysis. Then, water or an aqueous solution is added. The aqueous solution may comprise an acid, such as hydrochloric acid, sulfuric acid, nitric acid, citric acid, tartaric acid, oxalic acid, succinic acid, acetic acid, trifluoroacetic acid, or a buffer system, such as ammonium chloride, acetic acid / acetate, dihydrogen phosphate, hydrogen phosphate, TRIS (Tris (hydroxymethyl) -aminomethane), HEPES (2- (4- (2-hydroxyethyl) -1 acid -piperazinyl) -ethanesulfonic), or a base, such as NaHCO3, K2CO3, Na2CO3, KOH, NaOH. The reaction mixture is stirred, for example, for about 5 to 500 min, at an internal temperature of about -20 to 70 ° C, more preferably about 15-30 ° C.
After completion, the phases are separated and a partial or total amount of the organic solvent is distilled from the organic phase, preferably at a temperature below or equal to about 50 ° C, preferably under reduced pressure. The product of formula VII can be further purified and isolated. To this end, an organic solvent or a mixture of organic solvents is added to the residue, preferably at a temperature in the range of about 40 to 50 ° C. Preferred solvents are, for example, 2-propanol, methanol, 0 ethanol, 1-propanol, n-butanol, acetone, methyl ethyl ketone, isopropyl acetate, ethyl acetate, n-acetate butyl, ferc.-butylmethyl ether, n-heptane, methylcyclohexane, 2-methyltretrahydrofuran, acetonitrile, water, toluene, tetrahydrofuran, dioxane, methylene chloride, N-methylpyrrolidone, a N, N'-dimethylformamide or mixtures thereof The reaction mixture is cooled, preferably to a temperature in the range of about -25 to 40 ° C, more preferably to about -5 to 5 ° C. Cooling can occur in a period of about 0.1 to 20 hours. The product of formula VII can be collected, for example, on a filter or on a centrifuge, and washed with a suitable solvent or solvent mixture, such as 2-propanol and / or tert.-butyl methyl ether. The other suitable solvents have been described above. The product can be dried, preferably at a temperature below or equal to about 70 ° C, more preferably about 45 ° C, and under reduced pressure.
The formula VIII ketone can be synthesized starting from the formula IX benzoic acid derivative (Scheme 6) Scheme 5: Synthesis of the formula VIII ketone

Starting from the benzoic acid derivative of formula IX, where X means Br, I or triflate, preferably iodine, the corresponding chlorobenzoic acid is advantageously obtained by reaction with oxalyl chloride. This reaction is preferably carried out in the presence of a catalyst, such as dimethylformamide. The reaction conditions and solvents are well known to someone skilled in the art. For example, fluorbenzene can be considered as a solvent in the first reaction step i.), Which then forms the reagent (Z means fluorine) in the second reaction step ii.).
The second reaction step ii.) Can be characterized as Friedel-Crafts or Friedel-Crafts type acylation, a method well known in organic synthesis. In principle, chloro benzoic acid can be replaced by other benzoic acid derivatives, such as, for example, benzoyl anhydrides, esters, or benzonitriles. This reaction is advantageously carried out in the presence of a catalyst, such as AICI3, Fe-CI3, iodine, iron, ZnCI2, sulfuric acid, or trifluoromethanesulfonic acid, all of which are used in quantities catalytic or even stoichiometric. A preferred catalyst is AICI3. The reaction can be carried out with or without additional solvents. Additional solvents are chlorinated hydrocarbons, such as, for example, dichloromethane or 1,2-dichloroethane, or hydrocarbons, such as hexane or mixtures thereof. According to a preferred embodiment, the reaction is carried out using an excess of fluorbenzene, which additionally serves as a solvent. Preferred temperatures during the reaction range from -30 to 140 ° C, preferably from 15 to 60 ° C. After the completion of the reaction, the reaction mixture can be finished with water. Preferably, the organic solvents are removed. Intermediate VIII can be isolated, preferably by crystallization, for example, from water, the C1-3 alkanols and mixtures thereof, such as water / 2-propanol.
In addition, the compounds and intermediates obtained can be resolved into their enantiomers and / or diastereoisomers, as mentioned above. Thus, for example, cis / trans mixtures can be resolved into their cys trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
In this way, for example, cis / trans mixtures can be resolved by chromatography on their cise trans isomers, the compounds and intermediates obtained, which occur as racemates, can be separated by methods known per se (cf. Allinger NL and Eliel EL in "Pictures in Stereochemistry", Vol. 6, Wiley Interscience, 1971) in their optical antipopes, and compounds or intermediates with at least 2 asymmetric carbon atoms can be resolved in their diastereoisomers according to their physical-chemical differences, using known methods perse, for example, by chromatography and / or fractional crystallization, and, if these compounds are obtained in racemic form, they can subsequently be resolved in the enantiomers, as mentioned above.
The enantiomers are preferably separated by column separation over chiral phases or by recrystallization from an optically active solvent or by reaction with an optically active substance, which forms salts or derivatives, such as, for example, esters or amides with the racemic compound, particularly the acids and derivatives or the alcohols activated therefrom, and separation of the diastereoisomeric mixture of salts or derivatives thus obtained, for example, according to their differences in solubility, while the free antipodes can be released from the salts or pure diastereoisomeric derivatives by the action of suitable agents. Optically active acids in common use are, for example, forms D and L of tartaric acid or dibenzoyltartaric acid, di-o-tolyl tartaric acid, malic acid, mandelic acid, camphor sulfonic acid, glutamic acid, aspartic or quinic acid. An optically active alcohol can be, for example, (+) or (-) - menthol and an optically active acyl group in amides, for example, can be a (+) or (-) - mentyloxycarbonyl.
In addition, the compounds and intermediates of the present invention can be converted into their salts, particularly for pharmaceutical use, into the physiologically acceptable salts with inorganic or organic acids. Acids that can be used for this purpose include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
The compounds according to the invention are advantageously also obtainable using the methods described in the following examples, which can also be combined for this purpose with methods known to the person skilled in the literature, for example, particularly the methods described in WO 2006/120208, WO 2006/117359 and WO 2005/092877.
In the preceding and following text, the H atoms of the hydroxyl groups are not explicitly shown in each case in the structural formulas. The following Examples are intended to illustrate the present invention, without restricting it. The term "room temperature" means a temperature of approximately 20 ° C.
GC gas chromatography hour (s) i-Pr iso-propyl Me methyl min minute (s) THF tetrahydrofuran Experimental Procedures:
Example 1: Synthesis of fluoride VIII. 1
Oxalyl chloride (176 kg; 1386 moles; 1.14 eq) is added to a mixture of 2-chloro-5-iodo benzoic acid (343 kg; 1214 moles) (compound IX.1), fluorbenzene (858 kg) and N, N-dimethylformamide (2 kg), within 3 hours, at a temperature in the range of about 25 to 30 ° C (gas formation). After the addition is complete, the reaction mixture is stirred for an additional 2 hours at a temperature of about 25 to 30 ° C. The solvent (291 kg) is distilled at a temperature between 40 and 45 ° C [ = 20 kPa (200 mbar)]. Then, the reaction solution (911 kg) is added to aluminum chloride Al-CI3 (181 kg) and fluorbenzene (192 kg), at a temperature between about 25 and 30 ° C, within 2 hours. The reaction solution is stirred at the same temperature for an additional hour. Then, the reaction mixture is added to an amount of 570 kg of water, within about 2 hours, at a temperature between about 20 and 30 ° C, and stirred for an additional hour. After phase separation, the organic phase (1200 kg) is separated into two halves (600 kg each). From the first half of the organic phase, the solvent (172 kg) is distilled at a temperature of about 40 to 50 ° C [ = 20 kPa (200 mbar)]. Then, 2-propanol (640 kg) is added. The solution is heated to about 50 ° C and then filtered through a charcoal cartridge (clear filtration). The cartridge can be changed during filtration and washed with a fluorbenzene / 2-propanol mixture (1: 4; 40 kg) after filtration. The solvent (721 kg) is distilled at a temperature of about 40 to 50 ° C and p = 20 kPa (200 mbar). Then, 2-propanol (240 kg) is added at a temperature in the range of about 40 to 50 ° C. If the fluorbenzene content is greater than 1%, as determined by GC, another 140 kg of solvent is distilled and 2-propanol (140 kg) is added. Then, the solution is cooled from about 50 ° C to 40 ° C, within an hour, and the seeding crystals (50 g) are added. The solution is further cooled from about 40 ° C to 20 ° C, within 2 hours. Water (450 kg) is added at around 20 ° C within 1 hour, and the suspension is stirred at around 20 ° C for an additional hour, before the suspension is filtered. The filter cake is washed with 2-propanol / water (1: 1; 800 kg). The product is dried until a water level of <0.06% w / w is obtained. The second half of the organic phase is processed identically. A total of 410 kg (94% yield) of product, which has a white to not entirely white crystalline appearance, is obtained. The identity of the product is determined by means of infrared spectrometry. Example 2: Synthesis of ketone VII. 1
To a solution of fluoride VIII.1 (208 kg), tetrahydrofuran (407 kg) and (S) -3-hydroxytetrahydrofuran (56 kg) is added the solution of potassium tert-butanolate (20%) in tetrahydrofuran (388 kg) , within 3 h, at a temperature from 16 to 25 ° C. After the addition is complete, the mixture is stirred for 60 min at a temperature of 20 ° C. Then, the conversion is determined by means of HPLC analysis. Water (355 kg) is added within 20 min, at a temperature of 21 ° C (sudden water cooling). The reaction mixture is stirred for 30 min (temperature: 20 ° C). The stirrer is turned off and the mixture is left to stand for 60 min (temperature: 20 ° C). The phases are separated and the solvent is distilled from the organic phase at a temperature of 19 to 45 ° C, under reduced pressure. 2-Propanol (703 kg) is added to the residue, at a temperature of 40 to 46 ° C, and the solvent is distilled at a temperature of 41 to 50 ° C, under reduced pressure. 2-Propanol (162 kg) is added to the residue at a temperature of 47 ° C, and the solvent is distilled at a temperature of 40 to 47 ° C, under reduced pressure. Then, the mixture is cooled to 0 ° C, within 1 h and 55 min. The product is collected in a centrifuge, washed with a mixture of 2-propanol (158 kg) and subsequently with ferric-butyl methyl ether (88 kg) and dried at 19 to 43 ° C, under reduced pressure. 227 kg (91.8%) of the product is obtained as a colorless solid. The identity of the product is determined by means of infrared spectrometry. Example 3: Synthesis of iodide V.1
To a solution of ketone VII.1 (217.4 kg) and aluminum chloride (AICh; 81.5 kg) in toluene (366.8 kg) is added 1,1,3,3-tetrame-tildisiloxane (TMDS , 82.5 kg), within 1 h and 30 min (temperature: 18-26 ° C). After the addition is complete, the mixture is stirred for an additional 1 h at a temperature of 24 ° C. Then, the conversion is determined by means of HPLC analysis. Subsequently, the reaction mixture is treated with acetone (15.0 kg), stirred for 1 h and 5 min, at a temperature of 27 ° C, and the residual TMDS content is analyzed by GC. Then, a mixture of water (573 kg) and concentrated HCI (34 kg) is added to the reaction mixture, at a temperature of 20 to 51 ° C (sudden water cooling). The reaction mixture is stirred for 30 min (temperature: 51 ° C). The stirrer is turned off and the mixture is left to stand for 20 min (temperature: 52 ° C). The phases are separated and the solvent is distilled from the organic phase, at a temperature of 53-73 ° C, under reduced pressure. Toluene (52.8 kg) and ethanol (435.7 kg) are added to the residue, at a temperature of 61 to 70 ° C. The reaction mixture is cooled to a temperature of 36 ° C and the seeding crystals (0.25 kg) are added. Stirring is continued at this temperature for 35 min. Then, the mixture is cooled to 0 to 5 ° C and stirred for an additional 30 min. The product is collected in a centrifuge, washed with ethanol (157 kg) and dried at 15 to 37 ° C, under reduced pressure. 181 kg (82.6%) of product are obtained as a colorless solid. The identity of the product is determined by means of the HPLC retention time. Example 4: Synthesis of lactone IV. 1
A suspension of D - (+) - glyconic-delta-lactone IVa.1 (42.0 kg), tetrahydrofuran (277.2 kg), 4-methylmorpholine (NMM; 152.4 kg) and 4-dimethylaminopyridine (DMAP ; 1.44 kg) is treated with chlorotrimethylsilane (TMSCI; 130.8 kg) within 50 min, at 13 to 19 ° C. After completion of the addition, stirring is continued for 1 h and 30 min, at 20 to 22 ° C, and the conversion is determined by means of HPLC analysis. Then, n-heptane (216.4 kg) is added and the mixture is cooled to 5 ° C. Water (143 kg) is added at 3 to 5 ° C, within 15 min. After the addition is complete, the mixture is heated to 15 ° C and stirred for 15 min. The stirrer is turned off and the mixture is left to stand for 15 min. Then, the phases are separated and the organic layer is washed in succession, twice, with water (143 kg, each). Then, the solvent is distilled at 38 ° C, under reduced pressure, and n-heptane (130 kg) is added to the residue. The resulting solution is filtered and the filter is rinsed with n-heptane (63 kg) (the filter solution and the product solution are combined). Then, the solvent is distilled at 39 to 40 ° C, under reduced pressure. The water content of the residue is determined by Karl-Fischer analysis (result: 0.0%). 112.4 kg of the product are obtained as an oil (containing residual n-heptane, which explains the yield of> 100%). The product's identity is determined by means of infrared spectrometry. Example 5a: Synthesis of the 11.1 glycoside
To a solution of V.1 iodide (267 kg) in tetrahydrofuran (429 kg) is added Turbogrignard solution (isopropylmagnesium chloride / lithium chloride solution, 14% by weight of iPrMgCI in THF, LiCI molar ratio : iPrMgCI = 0.9 -1.1 mol / mol) (472 kg), at a temperature of -21 to -15 ° C, within 1 h and 50 min. At the end of the addition, the conversion is determined by means of HPLC analysis. The reaction is considered completed when the peak area corresponding to iodide V.1 is less than 5.0% of the total area of both peaks, iodide V.1 and the corresponding iodide V.1 diode compound. If the reaction is not completed, the additional Turbogrignard solution is added until the criterion is met. In this particular case, the result is 3.45%. So, lactone IV. 1 (320 kg) is added at a temperature of -25 to -18 ° C, within 1 h and 25 min. The resulting mixture is stirred for another 1 h and 30 min, at -13 to -18 ° C. At the end, the conversion is determined by means of HPLC analysis (for information). At the end, a solution of citric acid in water (938 L; concentration: 10% by weight) is added to the reaction mixture of a volume of about 2500 L, at -13 to 19 ° C, within 1 h and 25 min .
The solvent is partially distilled from the reaction mixture (residual volume: 1816-1905 L), at 20 to 30 ° C, under reduced pressure, and 2-methyltetrahydrofuran (532 kg) is added. Then, the stirrer is turned off and the phases are separated at 29 ° C. After phase separation, the pH value of the organic phase is measured with a pH electrode (Mettler Toledo MT HA 405 DPA SC) or alternatively with a pH indicator paper (such as pH-Fix 0-14, Macherey and Nagel ). The measured pH value is 2 to 3. Then, the solvent is distilled from the organic phase, at 30 to 33 ° C, under reduced pressure, and methanol (1202 kg) is added, followed by the addition of a solution of 1.25N HCI in methanol (75 kg) at 20 ° C (pH = 0). The total conversion to acetal 111.1 is achieved by subsequent distillation at 20 to 32 ° C, under reduced pressure, and addition of methanol (409 kg).
The completion of the reaction is achieved when two criteria are met: 1) The ratio of the sum of the HPLC area of the alpha + beta form of intermediate II 1.1 to the area of intermediate IIla. 1 is greater than or equal to 96.0%: 4.0%. 2) The ratio of the HPLC area from the alpha form of intermediate 111.1 to the beta form of III. 1 is greater than or equal to 97.0% to 3.0%.
In this particular case, both criteria are met. Triethylamine (14 kg) is added (pH = 7.4) and the solvent is distilled under reduced pressure, acetonitrile (835 kg) is added and further distilled under reduced pressure. This procedure is repeated (addition of acetonitrile: 694 kg) and methylene chloride (640 kg) is added to the resulting mixture to produce a mixture of acetal 111.1 in acetonitrile and methylene chloride. The water content of the mixture is determined by Karl Fischer titration (result: 0.27%).
The reaction mixture is then added within 1 h and 40 min, at 10 to 19 ° C, to a preformed mixture of AICI3 (176 kg), methylene chloride (474 kg), acetonitrile (340 kg), and triethylsilane (205 kg). The resulting mixture is stirred at 18 to 20 ° C for 70 min. After the end of the reaction, water (1263 L) is added at 20 to 30 ° C, within 1 h and 30 min, and the mixture is partially distilled at 30 to 53 ° C, under atmospheric pressure, and the phases are separated . Toluene (698 kg) is added to the organic phase and the solvent is distilled off under reduced pressure, at 22 to 33 ° C. The product is then crystallized by adding seeding crystals (0.5 kg) at 31 ° C, and water (267 kg) added after cooling to 20 ° C. The reaction mixture is cooled to 5 ° C within 55 min and stirred at 3 to 5 ° C for 12 h. Finally, the product is collected in a centrifuge as a colorless, crystalline solid, washed with toluene (348 kg) and dried at 22 to 58 ° C. 211 kg (73%) of the product is obtained. The identity of the product is determined through the HPLC retention time. Example 5b: Synthesis of 11.1 glycoside
To a solution of iodide V.1 (30 g) in tetrahydrofuran (55 ml) is added the Turbogrignard solution (isopropylmagnesium chloride / lithium chloride solution, 14 wt% iPrMgCI in THF, LiCI molar ratio : iPrMgCI = 0.9 - 1.1 mol / mol) (53 g), at a temperature of -14 to -13 ° C, within 35 min. At the end of the addition, the conversion is determined by means of HPLC analysis. The reaction is considered completed when the peak area corresponding to iodide V.1 is less than 5.0% of the total area of both peaks, iodide V.1 and the corresponding iodide iodide compound V.1 . If the reaction is not completed, the additional Turbogrignard solution is added until the criterion is met. In this particular case, the result is 0.35%. Then, lactone IV.1 (36 g) is added at a temperature of -15 to -6 ° C, within 15 min. The resulting mixture is stirred for an additional 1 h at -6 to -7 ° C. At the end, the conversion is determined by means of HPLC analysis (for information). At the end, a solution of citric acid in water (105 mL; concentration: 10% by weight) is added to the reaction mixture, at -15 to 10 ° C, within 30 min.
The solvent is partially distilled from the reaction mixture (residual volume: 200 ml), at 20 to 35 ° C, under reduced pressure, and 2-methyltetrahydrofuran (71 ml) is added. Then, the mixture is stirred for 25 min at 30 ° C. Then, the stirrer is turned off and the phases are separated at 30 ° C. After phase separation, the pH value of the organic phase is measured with a pH electrode (Mettler Toledo MT HA 405 DPA SC) or alternatively with a pH indicator paper (such as pH-Fix 0-14, Macherey and Nagel ). The measured pH value is 3. Then, the solvent is distilled from the organic phase, at 35 ° C, under reduced pressure, and methanol (126 mL) is added, followed by the addition of a 1.25N HCI solution in methanol (10.1 ml), at 25 ° C (pH = 1-2). The total conversion to acetal 111.1 is achieved by subsequent distillation at 35 ° C, under reduced pressure, and addition of methanol (47 mL).
The completion of the reaction is achieved when two criteria are met: 1) The ratio of the sum of the HPLC area of the alpha form + beta form of intermediate 111.1 to the area of intermediate llla.1 is greater than or equal to 96.0 %: 4.0%. In this particular case, the ratio is 99.6%: 0.43%. 2) The ratio of the HPLC area from the alpha form of intermediate 111.1 to the beta form of III. 1 is greater than or equal to 97.0% to 3.0%. In this particular case, the ratio is 98.7%: 1.3%.
Triethylamine (2.1 ml) is added (pH = 9) and the solvent is distilled at 35 ° C, under reduced pressure, acetonitrile (120 ml) is added and further distilled under reduced pressure, at 30 to 35 ° C . This procedure is repeated (addition of acetonitrile: 102 ml) and methylene chloride (55 ml) is added to the resulting mixture to produce a mixture of acetal 111.1 in acetonitrile and methylene chloride. The water content of the mixture is determined by Karl Fischer titration (result: 0.04%).
The reaction mixture is then added within 1 h and 5 min, at 20 ° C, to a preformed mixture of AICh (19.8 g), methylene chloride (49 ml), acetonitrile (51 ml), and triethylsilane (23 g). The resulting mixture is stirred at 20 to 30 ° C for 60 min. After the end of the reaction, water (156 mL) is added at 20 ° C, within 25 min, and the mixture is partially distilled at 55 ° C, under atmospheric pressure, and the phases are separated at 33 ° C. The mixture is heated to 43 ° C and toluene (90 ml) is added and the solvent is distilled under reduced pressure, at 41 to 43 ° C. Then, acetonitrile (10 mL) is added at 41 ° C and the percentage of acetonitrile is determined by means of GC measurement. In this particular case, the percentage of acetonitrile is 27% by weight. The product is then crystallized by adding seeding crystals (0.1 g) at 44 ° C and the mixture is further stirred at 44 ° C for 15 min. The mixture is then cooled to 20 ° C within 60 min and water (142 ml) is added to 20 ° C within 30 min. The reaction mixture is cooled to 0 to 5 ° C within 60 min and stirred at 3 ° C for 16 h. Finally, the product is collected on a filter as a colorless, crystalline solid, washed with toluene (80 ml) and dried at 20 to 70 ° C. 20.4 g (62.6%) of the product are obtained. The identity of the product is determined through the HPLC retention time.

权利要求:
Claims (19)
[0001]
1. Process for preparing a benzyl benzene derivative substituted with glycopyranosyl of the general formula III,
[0002]
2. Process according to claim 1, characterized by the fact that it additionally comprises step (S1): (S1): reacting a compound of formula V
[0003]
Process according to claim 2, characterized in that in step (S1) the compound of formula V is reacted with a C3-4-alkyl-magnesium chloride or bromide.
[0004]
4. Process according to claim 3, characterized by the fact that at the beginning of, during, or at the end of step (S1) and / or at the beginning or during step (S2), lithium bromide and / or lithium chloride is added to the reaction mixture, so the molar ratio of C3-4-alkyl magnesium chloride or bromide to lithium bromide and / or lithium chloride is from 1: 10 to 10: 1.
[0005]
Process according to claim 1, characterized in that the aqueous solution comprises 2 to 30% by weight of citric acid.
[0006]
Process according to claim 1, characterized in that the aqueous solution comprises 2 to 30% by weight of tartaric acid.
[0007]
Process according to one of Claims 1 to 6, characterized in that the organic phase of the reaction mixture in step (S3) comprises 2-methyltetrahydrofuran in an amount of 2 to 60% by weight in relation to the total amount of the organic phase of the reaction mixture.
[0008]
8. Process according to claim 1, characterized by the fact that the synthesis of a benzyl-benzene derivative substituted with glycopyranosyl of the general formula II,
[0009]
Process according to claim 1, characterized by the fact that the amount of gluconolactone relative to the organometallic compound of formula VI is 0.8 and 3 mol.
[0010]
10. Process according to claim 1, characterized by the fact that R 'means hydrogen, methyl or ethyl.
[0011]
11. Process according to claim 1, characterized by the fact that in step (S5) the adduct obtained reacts with an R'-OH alcohol, in which the R'-OH alcohol is selected from the group consisting of methanol, ethanol, 1- propanol, 2-propanol, n-butanol, tert-butanol or mixtures thereof.
[0012]
Process according to claim 1, characterized in that in step (S5) with the addition of one or more acids a pH of 0 to 7 is obtained.
[0013]
13. Process according to claim 1, characterized by the fact that in step (S5) the reaction temperature is -50 to 50 ° C.
[0014]
Process according to claim 2, characterized in that the amount of magnesium, lithium or a magnesium Grignard reagent in relation to the compound of formula V is 0.5 to 2 mol.
[0015]
15. Process according to claim 2, characterized by the fact that the reaction in step (S1) and / or step (S2) is carried out at a temperature between -70 and 10 ° C.
[0016]
16. Process according to claim 5, characterized in that the aqueous solution comprises 5 to 20% by weight of citric acid.
[0017]
17. Process according to claim 6, characterized in that the aqueous solution comprises 5 to 20% by weight of tartaric acid.
[0018]
18. Process according to claim 7, characterized in that the amount of 2-methyltetrahydrofuran is 10 and 40% by weight, in relation to the total amount of the organic phase of the reaction mixture.
[0019]
19. Process according to claim 1, characterized by the fact that the organic phase in step (S3) has a pH of 2 to 3.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012007085B1|2020-10-13|processes for the preparation of benzyl-benzene derivatives substituted with glycopyranosyl

---

Yuen et al.1998|On the absolute structure of optically active neolignans containing a dihydrobenzo [b] furan skeleton

---

RU2625795C2|2017-07-19|Method of obtaining sglt2 benzylenbenzole inhibitors

---

EP3148979B1|2019-02-06|Process for preparation of canagliflozin

---

EP2933250B1|2017-08-09|Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

---

JPWO2019208571A1|2021-04-30|Amidite compound and a method for producing a polynucleotide using the compound

---

JP6923520B2|2021-08-18|Novel 5-azido-5-deoxy-2: 3-isopropylidene-D-arabinose compounds, methods of their preparation, and their use for the synthesis of Ara-N3, Kdo-N3 and 4eKdo-N3.

---

JP2018532718A|2018-11-08|Phosphoramidate compound, production method thereof and crystal

---

CN107056730B|2019-05-24|A kind of synthetic method and its application of bupropion hydrochloride sustained release tablets impurity isomers

---

CN110139868A|2019-08-16|The method for preparing 5- amino -6H- thiazole simultaneously [4,5-d] pyrimidine -2,7- dione compounds of 3- substitution

---

JP5448420B2|2014-03-19|Hexahydroxydiphenoyl compound

---

KR20160098495A|2016-08-18|Process for the preparation of empagliflozin

---

TW202136222A|2021-10-01|Efficient process for making 6-carboxy benzoxazole derivatives

---

JP6898323B2|2021-07-07|Method for preparing 6-azido-2,4-diacetamide-2,4,6-trideoxy-D-mannose

---

JP2021530505A|2021-11-11|Chemical process to prepare phenylpiperidinyl indole derivatives

---

JP2021095367A|2021-06-24|Method for Producing C-aryl Glycoside Derivative

---

WO2021079617A1|2021-04-29|Glycoside compound, amidite compound, and production method for polynucleotide using said compounds

---

JP3936300B2|2007-06-27|Novel guanosine derivatives and uses thereof

---

CN102381954B|2014-07-09|Synthetic method for linderone and analogues thereof

---

JPH0745427B2|1995-05-17|Novel unsaturated inosose derivative and process for producing the same

---

JP2021534174A|2021-12-09|Production of intermediates useful for the synthesis of SGLT inhibitors

---

JP4402951B2|2010-01-20|Method for producing erythromycin compound

---

WO2005070911A1|2005-08-04|Transacetalisation process

---

JP2004123699A|2004-04-22|Method for producing diglycosylated gallic acid derivative

同族专利:

---

公开号 | 公开日

---

DK2486029T3|2015-08-24|

---

TW201127848A|2011-08-16|

---

SI2486029T1|2015-10-30|

---

CN102574829B|2015-07-01|

---

NZ598366A|2014-03-28|

---

EA201200537A1|2012-11-30|

---

CL2012000581A1|2012-08-03|

---

JP5758900B2|2015-08-05|

---

EP2486029B1|2015-06-10|

---

HUE026133T2|2016-05-30|

---

ES2546762T3|2015-09-28|

---

BR112012007085A2|2015-09-15|

---

IL218101D0|2012-04-30|

---

US9873714B2|2018-01-23|

---

AR078193A1|2011-10-19|

---

KR20120081592A|2012-07-19|

---

BR112012007085B8|2021-05-25|

---

CA2775962C|2017-09-05|

---

US9024010B2|2015-05-05|

---

CA2775962A1|2011-04-07|

---

US20110237789A1|2011-09-29|

---

WO2011039108A2|2011-04-07|

---

KR101813025B1|2017-12-28|

---

PL2486029T3|2015-11-30|

---

TWI465458B|2014-12-21|

---

PT2486029E|2015-10-14|

---

AU2010303124A1|2012-03-15|

---

HRP20150945T1|2015-10-09|

---

US20150218200A1|2015-08-06|

---

IN2012DN02751A|2015-09-18|

---

EA022032B1|2015-10-30|

---

JP2013505975A|2013-02-21|

---

AU2010303124B2|2014-01-23|

---

WO2011039108A3|2011-05-26|

---

MX2012003048A|2012-05-08|

---

EP2486029A2|2012-08-15|

---

CN102574829A|2012-07-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3174901A|1963-01-31|1965-03-23|Jan Marcel Didier Aron Samuel|Process for the oral treatment of diabetes|

---

NL167151C|1971-04-09|1981-11-16|Acf Chemiefarma Nv|PROCESS FOR THE PREPARATION OF MEDICINAL PRODUCTS WITH ANTI-PARASITARY ACTION ON THE BASIS OF HALOGEN CONTAINING THE 2,2'-METHYLENE DIFENOL DERIVATIVES, AND METHOD FOR PREPARING THESE MEDICINAL COMPOUNDS.|

---

NO154918C|1977-08-27|1987-01-14|Bayer Ag|ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.|

---

DE2758025A1|1977-12-24|1979-07-12|Bayer Ag|Tri:hydroxy-piperidine derivs. - useful as glucosidase inhibitors for treating diabetes etc. and as animal feed additives|

---

DE2951135A1|1979-12-19|1981-06-25|Hoechst Ag, 6230 Frankfurt|SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE|

---

JPS5748146B2|1980-07-16|1982-10-14|

---

JPH0153642B2|1982-03-26|1989-11-15|Chugai Pharmaceutical Co Ltd|

---

US4786755A|1985-06-03|1988-11-22|Warner-Lambert Company|Diphenic acid monoamides|

---

US4602023A|1985-06-03|1986-07-22|Warner-Lambert Company|Diphenic acid monoamides|

---

US4786023A|1987-08-19|1988-11-22|Harris Leverett D|Drafting implement holder|

---

US6297273B1|1996-04-02|2001-10-02|Mars, Inc.|Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions|

---

JPH1085502A|1996-09-19|1998-04-07|Konica Corp|Crystallization|

---

WO1998031697A1|1997-01-15|1998-07-23|Sankyo Company, Limited|Aryl c-glycoside compounds and sulfated esters thereof|

---

JPH11124392A|1997-10-21|1999-05-11|Sankyo Co Ltd|C-glycosylated aryltin compound|

---

DE19846314A1|1998-10-08|2000-04-13|Basf Ag|Production of polyolefin nano-composite, useful for production of film, mouldings and fibres, involves transition metal-catalysed polymerisation of olefin in presence of layered silicate|

---

US6613806B1|1999-01-29|2003-09-02|Basf Corporation|Enhancement of the efficacy of benzoylbenzenes|

---

AU782330B2|1999-08-31|2005-07-21|Kissei Pharmaceutical Co. Ltd.|Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof|

---

PH12000002657B1|1999-10-12|2006-02-21|Squibb Bristol Myers Co|C-aryl glucoside SGLT2 inhibitors|

---

US6515117B2|1999-10-12|2003-02-04|Bristol-Myers Squibb Company|C-aryl glucoside SGLT2 inhibitors and method|

---

US6498193B2|1999-12-22|2002-12-24|Trustees Of Dartmouth College|Treatment for complications of type 2 diabetes|

---

JP4456768B2|2000-02-02|2010-04-28|壽製薬株式会社|Drug containing C-glycoside|

---

US6627611B2|2000-02-02|2003-09-30|Kotobuki Pharmaceutical Co Ltd|C-glycosides and preparation of thereof as antidiabetic agents|

---

CN1177857C|2000-03-17|2004-12-01|橘生药品工业株式会社|Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the prepararation of the derivatives|

---

US6683056B2|2000-03-30|2004-01-27|Bristol-Myers Squibb Company|O-aryl glucoside SGLT2 inhibitors and method|

---

DE60122193T2|2000-09-29|2007-07-05|Kissei Pharmaceutical Co., Ltd., Matsumoto|GLUCOPYRANOSYLOXYBENZYLBENZEN DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS|

---

CA2429833A1|2000-11-30|2002-06-06|Kissei Pharmaceutical Co., Ltd.|Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof|

---

TWI255817B|2001-02-14|2006-06-01|Kissei Pharmaceutical|Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof|

---

EP1360172A1|2001-02-15|2003-11-12|Pfizer Products Inc.|Ppar agonists|

---

US6936590B2|2001-03-13|2005-08-30|Bristol Myers Squibb Company|C-aryl glucoside SGLT2 inhibitors and method|

---

JP3698067B2|2001-03-30|2005-09-21|Ｊｓｒ株式会社|Monomer having electron-withdrawing group and electron-donating group, copolymer using the same, and proton conducting membrane|

---

CA2444481A1|2001-04-11|2002-10-24|Bristol-Myers Squibb Company|Amino acid complexes of c-aryl glucosides for treatment of diabetes and method|

---

DE10139416A1|2001-08-17|2003-03-06|Aventis Pharma Gmbh|Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments|

---

US20030087843A1|2001-09-05|2003-05-08|Washburn William N.|O-pyrazole glucoside SGLT2 inhibitors and method of use|

---

WO2003031458A1|2001-10-12|2003-04-17|Dana-Farber Cancer Institute|Methods for synthesis of diarylmethanes|

---

WO2003064411A1|2002-02-01|2003-08-07|Novo Nordisk A/S|Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes|

---

GB0206215D0|2002-03-15|2002-05-01|Novartis Ag|Organic compounds|

---

DE10231370B4|2002-07-11|2006-04-06|Sanofi-Aventis Deutschland Gmbh|Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments|

---

TWI254635B|2002-08-05|2006-05-11|Yamanouchi Pharma Co Ltd|Azulene derivative and salt thereof|

---

KR100985502B1|2002-08-08|2010-10-05|깃세이 야쿠힌 고교 가부시키가이샤|Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof|

---

KR101111101B1|2002-08-21|2012-06-13|베링거 잉겔하임 파르마 게엠베하 운트 코 카게|A pharmaceutical composition and a combination comprising 8-[3-amino-piperidin-1-yl]-xanthines, and the production of the pharmaceutical composition|

---

US7407955B2|2002-08-21|2008-08-05|Boehringer Ingelheim Pharma Gmbh & Co., Kg|8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions|

---

JP3567162B1|2002-11-20|2004-09-22|日本たばこ産業株式会社|4-oxoquinoline compounds and their use as HIV integrase inhibitors|

---

EP2161258A3|2002-11-20|2010-04-07|Japan Tabacco Inc.|4-oxoquinoline compound and use thereof as hiv integrase inhibitor|

---

JP4651934B2|2002-12-04|2011-03-16|キッセイ薬品工業株式会社|Benzylphenol derivative, pharmaceutical composition containing it, and pharmaceutical use thereof|

---

DE10258008B4|2002-12-12|2006-02-02|Sanofi-Aventis Deutschland Gmbh|Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments|

---

DE10258007B4|2002-12-12|2006-02-09|Sanofi-Aventis Deutschland Gmbh|Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments|

---

EP1581543A4|2003-01-03|2008-03-19|Squibb Bristol Myers Co|Methods of producing c-aryl glucoside sglt2 inhibitors|

---

US7164015B2|2003-02-27|2007-01-16|Bristol-Myers Squibb Company|Non-cryogenic process for forming glycosides|

---

ZA200507754B|2003-03-14|2007-01-31|Astellas Pharma Inc|C-glycoside derivatives and salts thereof|

---

US7674486B2|2003-05-14|2010-03-09|Indus Biotech Pvt. Ltd.|Synergistic composition for the treatment of diabetes mellitus|

---

CA2528152A1|2003-06-03|2005-01-06|The Regents Of The University Of California|Compositions and methods for treatment of disease with acetylated disaccharides|

---

JP2004359630A|2003-06-06|2004-12-24|Yamanouchi Pharmaceut Co Ltd|Difluorodiphenylmethane derivative and its salt|

---

US7094763B2|2003-08-01|2006-08-22|Janssen Pharaceutica, N.V.|Substituted fused heterocyclic C-glycosides|

---

EP1680414A4|2003-08-01|2009-05-27|Janssen Pharmaceutica Nv|Substituted indazole-o-glucosides|

---

ES2402098T5|2003-08-01|2021-06-09|Mitsubishi Tanabe Pharma Corp|Novel compounds that have inhibitory activity against the sodium-dependent transporter|

---

JP4131216B2|2003-08-20|2008-08-13|Ｊｓｒ株式会社|Polyarylene, production method thereof, solid polymer electrolyte and proton conducting membrane|

---

US7375090B2|2003-08-26|2008-05-20|Boehringer Ingelheim International Gmbh|Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof|

---

DE502004008951D1|2003-08-26|2009-03-19|Boehringer Ingelheim Pharma|GLUCOPYRANOSYLOXY-PYRAZOLE, MEDICAMENT CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF|

---

US20050085680A1|2003-10-21|2005-04-21|Joseph Auerbach|Method for industrial decontamination|

---

DE10361133A1|2003-12-22|2005-07-21|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Glucopyranosyloxy-substituted aromatics, medicaments containing these compounds, their use and processes for their preparation|

---

US7371732B2|2003-12-22|2008-05-13|Boehringer Ingelheim International Gmbh|Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture|

---

ZA200608028B|2004-03-04|2009-03-25|Kissei Pharmaceutical|Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof|

---

JP5078350B2|2004-03-04|2012-11-21|キッセイ薬品工業株式会社|Fused heterocyclic derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof|

---

DE102004012676A1|2004-03-16|2005-10-06|Boehringer Ingelheim Pharma Gmbh & Co. Kg|New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders |

---

PL1730131T3|2004-03-16|2012-10-31|Boehringer Ingelheim Int|Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof|

---

US7393836B2|2004-07-06|2008-07-01|Boehringer Ingelheim International Gmbh|D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

JPWO2006006496A1|2004-07-08|2008-04-24|アステラス製薬株式会社|Method for producing azulene derivatives and synthetic intermediates thereof|

---

DE102004034690A1|2004-07-17|2006-02-02|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Methylidene-D-xylopyranosyl and oxo-D-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and processes for their preparation|

---

TW200606129A|2004-07-26|2006-02-16|Chugai Pharmaceutical Co Ltd|Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same|

---

EP1773800A1|2004-07-27|2007-04-18|Boehringer Ingelheim International GmbH|D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof|

---

WO2006018150A1|2004-08-11|2006-02-23|Boehringer Ingelheim International Gmbh|D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof|

---

AR051446A1|2004-09-23|2007-01-17|Squibb Bristol Myers Co|C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS |

---

EP1803729A4|2004-09-29|2008-10-01|Kissei Pharmaceutical|1--3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof|

---

DE102004048388A1|2004-10-01|2006-04-06|Boehringer Ingelheim Pharma Gmbh & Co. Kg|D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation|

---

EP1828216B1|2004-12-16|2008-09-10|Boehringer Ingelheim International GmbH|Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

JP2006176443A|2004-12-22|2006-07-06|Shionogi & Co Ltd|Melanin-concentrating hormone receptor antagonist|

---

GB0428180D0|2004-12-23|2005-01-26|Biopartners Ltd|Combination therapy|

---

GT200600008A|2005-01-18|2006-08-09|FORMULATION OF DIRECT COMPRESSION AND PROCESS|

---

CA2595257A1|2005-02-23|2006-08-31|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 inhibitors|

---

CA2605245A1|2005-04-15|2006-10-19|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted -benzene derivatives as sglt inhibitors|

---

US7723309B2|2005-05-03|2010-05-25|Boehringer Ingelheim International Gmbh|Crystalline forms of 1-chloro-4--2-[4--tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments|

---

US7713938B2|2005-05-03|2010-05-11|Boehringer Ingelheim International Gmbh|Crystalline form of 1-chloro-4--2-[4--tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments|

---

US7772191B2|2005-05-10|2010-08-10|Boehringer Ingelheim International Gmbh|Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein|

---

WO2007000445A1|2005-06-29|2007-01-04|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

WO2007014894A2|2005-07-27|2007-02-08|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter inhibitors|

---

KR100780553B1|2005-08-18|2007-11-29|한올제약주식회사|Pharmaceutical compositions and formulations of Metformin extended release tablets and its preparing method|

---

US7452872B2|2005-08-24|2008-11-18|Salix Pharmaceuticals, Inc.|Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives|

---

WO2007025943A2|2005-08-30|2007-03-08|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

US8507450B2|2005-09-08|2013-08-13|Boehringer Ingelheim International Gmbh|Crystalline forms of 1-chloro-4--2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments|

---

AR056195A1|2005-09-15|2007-09-26|Boehringer Ingelheim Int|PROCEDURES TO PREPARE DERIVATIVES OF -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME|

---

JOP20180109A1|2005-09-29|2019-01-30|Novartis Ag|New Formulation|

---

BRPI0617208A2|2005-09-30|2011-07-19|Boehringer Ingelheim Vetmed|pharmaceutical preparation containing meloxicam|

---

PE20080697A1|2006-05-03|2008-08-05|Boehringer Ingelheim Int|BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE|

---

TW200801029A|2006-02-15|2008-01-01|Boehringer Ingelheim Int|Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture|

---

EP1852108A1|2006-05-04|2007-11-07|Boehringer Ingelheim Pharma GmbH & Co.KG|DPP IV inhibitor formulations|

---

PE20080251A1|2006-05-04|2008-04-25|Boehringer Ingelheim Int|USES OF DPP IV INHIBITORS|

---

DE602007012692D1|2006-06-16|2011-04-07|Lek Pharmaceuticals|PHARMACEUTICAL COMPOSITION WITH HYDROCHLOROTHIAZIDE AND TELMISARTAN|

---

PE20120542A1|2006-06-27|2012-05-14|Novartis Ag|SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF PREPARING THEM|

---

TW200817424A|2006-08-04|2008-04-16|Daiichi Sankyo Co Ltd|Benzylphenyl glucopyranoside derivatives|

---

CA2656847A1|2006-08-15|2008-02-21|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture|

---

EP2056673A4|2006-08-17|2010-06-16|Wellstat Therapeutics Corp|Combination treatment for metabolic disorders|

---

CA2664095A1|2006-09-21|2008-03-27|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

US8283326B2|2006-10-27|2012-10-09|Boehringer Ingelheim International Gmbh|Crystalline form of 4--1-methyl-2-[4--tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments|

---

WO2008101938A1|2007-02-21|2008-08-28|Boehringer Ingelheim International Gmbh|Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

EP2079753A1|2006-11-06|2009-07-22|Boehringer Ingelheim International GmbH|Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

CN101534815A|2006-11-09|2009-09-16|贝林格尔.英格海姆国际有限公司|Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions|

---

WO2008062273A2|2006-11-20|2008-05-29|Cadila Pharmaceuticals Limited|Solid oral dosage form having antidiabetic drug combination|

---

AT514692T|2007-01-26|2011-07-15|Sanofi Aventis|PHENOTHIAZIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS|

---

TW200838549A|2007-01-26|2008-10-01|Boehringer Ingelheim Int|Methods for preventing and treating neurodegenerative disorders|

---

ITFI20070042A1|2007-02-21|2008-08-22|Laboratori Guidotti Spa|PHARMACEUTICAL FORMULATION AND COMPRESSED INCLUDING THIS FORMULATION.|

---

WO2008101939A1|2007-02-21|2008-08-28|Boehringer Ingelheim International Gmbh|Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture|

---

US8551524B2|2008-03-14|2013-10-08|Iycus, Llc|Anti-diabetic combinations|

---

AR065809A1|2007-03-22|2009-07-01|Squibb Bristol Myers Co|PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR|

---

TW200904454A|2007-03-22|2009-02-01|Squibb Bristol Myers Co|Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof|

---

PE20090696A1|2007-04-20|2009-06-20|Squibb Bristol Myers Co|CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM|

---

JP2010528023A|2007-05-18|2010-08-19|ブリストル−マイヤーズスクイブカンパニー|Crystal structure of SGLT2 inhibitor and method for producing the same|

---

PE20090603A1|2007-08-16|2009-06-11|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITION INCLUDING A SGLT2 INHIBITOR AND A DPP IV INHIBITOR|

---

PE20090938A1|2007-08-16|2009-08-08|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL|

---

DK2200606T3|2007-09-10|2017-12-04|Janssen Pharmaceutica Nv|PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT|

---

CL2008003653A1|2008-01-17|2010-03-05|Mitsubishi Tanabe Pharma Corp|Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.|

---

CA2713361A1|2008-02-05|2009-08-13|Merck Sharp & Dohme Corp.|Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor|

---

EP2261213A1|2008-04-01|2010-12-15|Takeda Pharmaceutical Company Limited|Heterocyclic compound|

---

PE20091730A1|2008-04-03|2009-12-10|Boehringer Ingelheim Int|FORMULATIONS INVOLVING A DPP4 INHIBITOR|

---

WO2010045656A2|2008-10-17|2010-04-22|Nectid, Inc.|Novel sglt2 inhibitor dosage forms|

---

CN102387783A|2009-02-13|2012-03-21|贝林格尔.英格海姆国际有限公司|Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient|

---

UY32427A|2009-02-13|2010-09-30|Boheringer Ingelheim Internat Gmbh|PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME|

---

SG10201600204YA|2009-02-13|2016-02-26|Boehringer Ingelheim Int|SGLT-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Impaired Glucose Tolerance Or Hyperglycemia|

---

HUE050287T2|2009-02-13|2020-11-30|Boehringer Ingelheim Int|Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof|

---

EP2395988A2|2009-02-13|2011-12-21|Boehringer Ingelheim International GmbH|Antidiabetic medications comprising a dpp-4 inhibitor optionally in combination with other antidiabetics|

---

EP2829271A3|2009-04-16|2015-05-27|Taisho Pharmaceutical Co., Ltd.|Pharmaceutical compositions with -1,5-anhydro-1-[5--2-methoxy-4-methylphenyl]-1-thio-D-glucitol and a further antidiabetic agent|

---

CN102639125A|2009-05-27|2012-08-15|百时美施贵宝公司|Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof|

---

US20110077212A1|2009-09-25|2011-03-31|Theracos, Inc.|Therapeutic uses of sglt2 inhibitors|

---

BR112012007085B8|2009-09-30|2021-05-25|Boehringer Ingelheim Int|processes for the preparation of glycopyranosyl substituted benzyl-benzene derivatives|

---

HUE029381T2|2009-09-30|2017-02-28|Boehringer Ingelheim Int|Method for the preparation of a crystalline form of 1-chloro-4--2--tetrahydrofuran-3-yloxy)benzyl)benzene|

---

UY32919A|2009-10-02|2011-04-29|Boehringer Ingelheim Int|Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses|

---

SI2498759T1|2009-11-13|2018-12-31|Astrazeneca Ab|Immediate release tablet formulations|

---

WO2011120923A1|2010-03-30|2011-10-06|Boehringer Ingelheim International Gmbh|Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof|

---

MX2013002146A|2010-09-03|2013-04-03|Astrazeneca Uk Ltd|Drug formulations using water soluble antioxidants.|

---

US20120283169A1|2010-11-08|2012-11-08|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

AR083878A1|2010-11-15|2013-03-27|Boehringer Ingelheim Int|VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD|

---

AU2012212448B9|2011-02-01|2015-06-25|Astrazeneca Uk Limited|Pharmaceutical formulations including an amine compound|

---

US20130035281A1|2011-02-09|2013-02-07|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

UY33937A|2011-03-07|2012-09-28|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS|

---

CN103596574A|2011-06-03|2014-02-19|勃林格殷格翰国际有限公司|SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents|

---

US20130035298A1|2011-07-08|2013-02-07|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

DE102011109492A1|2011-08-04|2013-02-07|GM Global Technology Operations LLC |Driving assistance device to support the driving of narrow roads|

---

US9555001B2|2012-03-07|2017-01-31|Boehringer Ingelheim International Gmbh|Pharmaceutical composition and uses thereof|

---

US9192617B2|2012-03-20|2015-11-24|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

US20140303097A1|2013-04-05|2014-10-09|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

TR201901110T4|2013-04-05|2019-02-21|Boehringer Ingelheim Int|Therapeutic uses of empagliflozin.|

---

US20160000816A1|2013-04-05|2016-01-07|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

CA2909728A1|2013-04-18|2014-10-23|Boehringer Ingelheim International Gmbh|Therapeutic uses of empagliflozin|

---

DK3125882T3|2014-04-01|2020-06-29|Boehringer Ingelheim Vetmedica Gmbh|TREATMENT OF METABOLIC DISORDERS IN ANIMAL ANIMALS|

---

WO2017064193A1|2015-10-15|2017-04-20|Boehringer Ingelheim International Gmbh|Sglt-2 inhibitor for use in the treatment of a metabolic myopathy|PL1730131T3|2004-03-16|2012-10-31|Boehringer Ingelheim Int|Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof|

---

US7713938B2|2005-05-03|2010-05-11|Boehringer Ingelheim International Gmbh|Crystalline form of 1-chloro-4--2-[4--tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments|

---

US7772191B2|2005-05-10|2010-08-10|Boehringer Ingelheim International Gmbh|Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein|

---

US8507450B2|2005-09-08|2013-08-13|Boehringer Ingelheim International Gmbh|Crystalline forms of 1-chloro-4--2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments|

---

PE20080697A1|2006-05-03|2008-08-05|Boehringer Ingelheim Int|BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE|

---

US8283326B2|2006-10-27|2012-10-09|Boehringer Ingelheim International Gmbh|Crystalline form of 4--1-methyl-2-[4--tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments|

---

PE20090938A1|2007-08-16|2009-08-08|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL|

---

CA2706018C|2007-11-30|2015-11-24|Boehringer Ingelheim International Gmbh|1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders|

---

AU2010230290B2|2009-03-31|2013-03-14|Boehringer Ingelheim International Gmbh|1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators|

---

AR071577A1|2008-04-02|2010-06-30|Boehringer Ingelheim Int|PIRAZOLO-PYRIMIDINONE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM|

---

BRPI0918527A2|2008-09-08|2015-12-01|Boehring Ingelheim Internat Gmbh|compounds for the treatment of cns disorders|

---

HUE050287T2|2009-02-13|2020-11-30|Boehringer Ingelheim Int|Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof|

---

HUE029381T2|2009-09-30|2017-02-28|Boehringer Ingelheim Int|Method for the preparation of a crystalline form of 1-chloro-4--2--tetrahydrofuran-3-yloxy)benzyl)benzene|

---

BR112012007085B8|2009-09-30|2021-05-25|Boehringer Ingelheim Int|processes for the preparation of glycopyranosyl substituted benzyl-benzene derivatives|

---

UY32919A|2009-10-02|2011-04-29|Boehringer Ingelheim Int|Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses|

---

UA110347C2|2010-08-12|2015-12-25|Бьорінгер Інгельхайм Інтернаціональ Гмбх|Derivative 6-cycloalkanes 1.5 dyhidropirazol [3,4-d] pyrimidine-4-one and their use as inhibitors pde9a|

---

US8809345B2|2011-02-15|2014-08-19|Boehringer Ingelheim International Gmbh|6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders|

---

UY33937A|2011-03-07|2012-09-28|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS|

---

CN103596574A|2011-06-03|2014-02-19|勃林格殷格翰国际有限公司|SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents|

---

US20130035298A1|2011-07-08|2013-02-07|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

US9555001B2|2012-03-07|2017-01-31|Boehringer Ingelheim International Gmbh|Pharmaceutical composition and uses thereof|

---

US9192617B2|2012-03-20|2015-11-24|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

US9193751B2|2012-04-10|2015-11-24|Theracos, Inc.|Process for the preparation of benzylbenzene SGLT2 inhibitors|

---

WO2013152476A1|2012-04-10|2013-10-17|Theracos, Inc.|Process for the preparation of benzylbenzene sglt2 inhibitors|

---

WO2014161836A1|2013-04-04|2014-10-09|Boehringer Ingelheim Vetmedica Gmbh|Treatment of metabolic disorders in equine animals|

---

TR201901110T4|2013-04-05|2019-02-21|Boehringer Ingelheim Int|Therapeutic uses of empagliflozin.|

---

US20140303097A1|2013-04-05|2014-10-09|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

CA2909728A1|2013-04-18|2014-10-23|Boehringer Ingelheim International Gmbh|Therapeutic uses of empagliflozin|

---

CA2889699C|2013-09-27|2017-06-06|Sunshine Lake Pharma Co., Ltd.|Glucopyranosyl derivatives and their uses in medicine|

---

CA2930034A1|2013-12-17|2015-06-25|Boehringer Ingelheim Vetmedica Gmbh|Treatment of metabolic disorders in feline animals|

---

WO2015101916A1|2013-12-30|2015-07-09|Mylan Laboratories Ltd.|Process for the preparation of empagliflozin|

---

EP3485890A1|2014-01-23|2019-05-22|Boehringer Ingelheim Vetmedica GmbH|Treatment of metabolic disorders in canine animals|

---

DK3125882T3|2014-04-01|2020-06-29|Boehringer Ingelheim Vetmedica Gmbh|TREATMENT OF METABOLIC DISORDERS IN ANIMAL ANIMALS|

---

US10053535B2|2016-01-04|2018-08-21|National Technology & Engineering Solutions Of Sandia, Llc|Poly-based anion exchange polymers and methods thereof|

---

US10294325B2|2016-01-04|2019-05-21|National Technology & Engineering Solutions Of Sandia, Llc|Halo-containing anion exchange membranes and methods thereof|

---

EP3400252A4|2016-01-04|2019-08-28|National Technology & Engineering Solutions of Sandia, LLC|Functionalization of diels-alder polyphenylene polymers|

---

EP3526229B1|2016-10-13|2021-04-28|Boehringer Ingelheim International GmbH|Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives|

---

CN109843279A|2016-10-19|2019-06-04|勃林格殷格翰国际有限公司|Pharmaceutical composition comprising SSAO/VAP-1 inhibitor and SGLT2 inhibitor, its purposes|

---

US20180125813A1|2016-11-10|2018-05-10|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|

---

US11046676B2|2017-06-05|2021-06-29|Laurus Labs Limited|Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof|

---

CN107163033A|2017-06-15|2017-09-15|扬子江药业集团北京海燕药业有限公司|A kind of preparation method net high-purity Yi Palie|

---

CN109988161A|2017-12-29|2019-07-09|徐州万邦金桥制药有限公司|A kind of preparation method that suitable industrialized production En Gelie is net|

---

CN108178751A|2018-01-30|2018-06-19|扬州工业职业技术学院|A kind of synthetic method of the net intermediates of En Gelie|

---

US10479866B1|2018-02-28|2019-11-19|National Technology & Engineering Solutions Of Sandia, Llc|Block copolymers including poly and methods thereof|

---

EP3781166A1|2018-04-17|2021-02-24|Boehringer Ingelheim International GmbH|Pharmaceutical composition, methods for treating and uses thereof|

---

WO2020020896A1|2018-07-25|2020-01-30|Boehringer Ingelheim International Gmbh|Empagliflozin for use in treating alport syndrome|

---

WO2020039394A1|2018-08-24|2020-02-27|Novartis Ag|New drug combinations|

---

CN109456314A|2018-10-19|2019-03-12|威海迪素制药有限公司|A kind of preparation method that En Gelie is net|

---

CN110655511B|2019-05-31|2020-10-16|北京莱瑞森医药科技有限公司|Preparation and refining method of high-purity empagliflozin|

---

UY38969A|2019-11-28|2021-05-31|Boehringer Ingelheim Vetmedica Gmbh|USE OF SGLT-2 INHIBITORS IN DRYING NON-HUMAN MAMMALS|

---

CN110759941A|2019-11-29|2020-02-07|上海网义化工有限公司|Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof|

---

CN110872216A|2019-12-06|2020-03-10|南京恒道医药科技有限公司|Method and device for producing-4-fluorobenzyl ketone by reaction separation coupling|

---

WO2021165177A1|2020-02-17|2021-08-26|Boehringer Ingelheim Vetmedica Gmbh|Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines|

---

WO2021204756A1|2020-04-07|2021-10-14|Boehringer Ingelheim International Gmbh|Methods for the treatment of headache disorders|

---

CN111410639B|2020-04-14|2021-02-26|天津法莫西医药科技有限公司|Preparation method of empagliflozin intermediate impurity|

---

CN112194655A|2020-10-15|2021-01-08|通化东宝药业股份有限公司|Preparation method of empagliflozin intermediate|

法律状态:
2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-11-27| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2019-02-12| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2019-12-17| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-01-28| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2020-05-19| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-10-13| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |

---

2021-05-25| B16C| Correction of notification of the grant|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |

优先权:

---

申请号 | 申请日 | 专利标题

---

US24714409P| true| 2009-09-30|2009-09-30|

---

US61/247,144|2009-09-30|

---

PCT/EP2010/064120|WO2011039108A2|2009-09-30|2010-09-24|Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives|

---